Ann: Imugene B Cell & OV Platforms Featured at ESMO Congress, page-125

First 125 Last

Share
Profile

Follow
Zior

1,391 Posts.

10577

25/10/23

23:35

Post #: 70540692
Share

Originally posted by DDD24: ↑

The statement you provided describes the results of a vaccination approach in patients with HER-2-overexpressing gastric cancer (GC).

Let's break down what this means:HER-Vaxx-based vaccination: This refers to a vaccination strategy that is designed to target HER-2/neu, a protein that is overexpressed in some cancer cells, including gastric cancer.

The vaccination likely involves administering a vaccine (HER-Vaxx) to the patients.HER-2-overexpressing GC: This specifies the type of cancer being targeted. It's gastric cancer (GC) in which the HER-2/neu protein is overexpressed. Overexpression of HER-2/neu is associated with more aggressive cancer and is a therapeutic target.Induced anti-HER-2-IgG and IgG1 subclass antibody responses (p<0.001):

This indicates that the vaccination led to the production of antibodies against the HER-2 protein. IgG antibodies are a class of antibodies in the immune system, and IgG1 is a subclass of IgG. The "p<0.001" suggests that the production of these antibodies was statistically significant, indicating a strong immune response.Dose-dependent functionality in binding to Her-2/neu-expressing cells:

This means that the antibodies produced by the vaccination have the ability to bind effectively to cancer cells that overexpress the HER-2/neu protein. Moreover, the effectiveness of this binding increases with the vaccine dose, showing a dose-dependent response.Intracellular phosphorylation inhibition of the receptor and the signaling pathway kinases Akt and MAPK:

This indicates that the antibodies generated by the vaccination are not only binding to the HER-2/neu protein on the surface of cancer cells but are also capable of inhibiting the phosphorylation of the receptor and the downstream signaling pathway kinases Akt and MAPK.

This is a critical result because it suggests that the vaccination is interfering with the cancer cell's growth and signaling processes.

In summary, the HER-Vaxx-based vaccination in patients with HER-2-overexpressing gastric cancer appears to be effective. It induces a strong immune response, resulting in the production of antibodies that can bind to cancer cells and, importantly, inhibit the intracellular signaling pathways related to cell growth. This is a promising development in the treatment of HER-2/neu-positive gastric cancer

Expand

@DDD24
Thankyou for taking your time to break this down. There are many here who appear to have a solid grasp of the science and share what they know and I'm sure we all appreciate the effort. You have managed to do so succinctly and in a way that even I can grasp easily without needing to sit down and read several times just to process.

I am truly grateful. Please do stick around and continue to share your analysis. I ask this, because being a meaningful part of the discussion here has recently become a burden to many who want to share. Thanks again.

TU mate

Last edited by Zior: 25/10/23

IMU Price at posting: 4.4¢ Sentiment: Buy Disclosure: Held
74 Upvote

4 Great analysis

Reply

Top Stories

Super PITch gold sponsor RSM Australia: Can Diggers & Dealers 2024 be key to reinvigorating IPO activity?

NWH

NRW Holdings voted Wealth Within's hot stock tip

KSN

Mineral Hill transition kicks off for Kingston, gold and silver ramp up to follow

MTL

Mantle Minerals' Nick Poll talks to HotCopper on finding gold grades up to 3.57g/t at Mt Berghaus

AIZ

Air New Zealand ditches 2030 emissions targets – right as ASIC's Scope 3 reporting changes kick in for FY25

There are more pages in this discussion • 64 more messages in this thread...

First 125 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.3¢		Change -0.001(1.85%)		Mkt cap ! $389.5M

Open	High	Low	Value	Volume
5.5¢	5.6¢	5.3¢	$615.0K	11.39M

Buyers (Bids)

No.	Vol.	Price($)
25	2977440	5.3¢

Sellers (Offers)

Price($)	Vol.	No.
5.4¢	283236	4

View Market Depth

No.	Vol.	Price($)
25	2977440	0.053
25	3109336	0.052
24	2300422	0.051
66	4218756	0.050
23	3155527	0.049

Price($)	Vol.	No.
0.054	283236	4
0.055	1134647	7
0.056	1642592	7
0.057	1624353	11
0.058	230000	3

Last trade - 16.10pm 30/07/2024 (20 minute delay)

IMU (ASX) Chart

Ann: Imugene B Cell & OV Platforms Featured at ESMO Congress, page-125

Super PITch gold sponsor RSM Australia: Can Diggers & Dealers 2024 be key to reinvigorating IPO activity?

NRW Holdings voted Wealth Within's hot stock tip

Mineral Hill transition kicks off for Kingston, gold and silver ramp up to follow

Mantle Minerals' Nick Poll talks to HotCopper on finding gold grades up to 3.57g/t at Mt Berghaus

Air New Zealand ditches 2030 emissions targets – right as ASIC's Scope 3 reporting changes kick in for FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Imugene B Cell & OV Platforms Featured at ESMO Congress, page-125

Top Stories

Super PITch gold sponsor RSM Australia: Can Diggers & Dealers 2024 be key to reinvigorating IPO activity?

NRW Holdings voted Wealth Within's hot stock tip

Mineral Hill transition kicks off for Kingston, gold and silver ramp up to follow

Mantle Minerals' Nick Poll talks to HotCopper on finding gold grades up to 3.57g/t at Mt Berghaus

Air New Zealand ditches 2030 emissions targets – right as ASIC's Scope 3 reporting changes kick in for FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News